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Abstract
 
The receptor subunit gp130 transduces multiple cell type–specific activities of the leukemia in-
hibitory factor (LIF)/interleukin (IL)-6 family of cytokines through the signal transducer and
activator of transcription (STAT) and src homology 2 domain–bearing protein tyrosine phos-
phatase (SHP)-2/ras/Erk pathways. To define STAT-dependent physiological responses, we
generated mice with a COOH-terminal gp130
 
 
 
STAT
 
 “knock-in” mutation which deleted all
STAT-binding sites. gp130
 
 
 
STAT
 
 mice phenocopyed mice deficient for IL-6 (impaired humoral
and mucosal immune and hepatic acute phase responses) and LIF (failure of blastocyst implan-
tation). However, unlike mice with null mutations in any of the components in the gp130 sig-
naling pathway, gp130
 
 
 
STAT
 
 mice also displayed gastrointestinal ulceration and a severe joint
disease with features of chronic synovitis, cartilaginous metaplasia, and degradation of the artic-
ular cartilage. Mitogenic hyperresponsiveness of synovial cells to the LIF/IL-6 family of cyto-
kines was caused by sustained gp130-mediated SHP-2/ras/Erk activation due to impaired
STAT-mediated induction of suppressor of cytokine signaling (SOCS) proteins which nor-
mally limits gp130 signaling. Therefore, the joint pathology in gp130
 
 
 
STAT
 
 mice is likely to
arise from the disturbance of the otherwise balanced activation of the SHP-2/ras/Erk and
STAT signaling cascades emanating from gp130.
Key words: infertility • signal transduction • STAT • interleukin • gene targeting
 
Introduction
 
The activities of a family of cytokines that comprises IL-6,
IL-11, leukemia inhibitory factor (LIF),
 
*
 
 oncostatin M
(OsM), ciliary neurotrophic factor (CNTF), and cardiotro-
phin-1 are mediated by the common signal transducing
receptor 
 
 
 
 chain gp130 (1, 2). LIF/IL-6 cytokines exert
multiple activities on target organs such as liver, heart,
immune, hematopoietic, and nervous systems that are piv-
otal during embryogenesis, morphogenesis, and inflamma-
tion. Aberrant expression of LIF/IL-6 family cytokines has
been associated with autoimmune disease, septic shock, and
neoplasia (2, 3). Somewhat surprisingly, mice with engi-
neered null mutations for individual LIF/IL-6 family
ligands or receptor 
 
 
 
 subunits develop normally and ex-
hibit rather mild phenotypes. IL-6–deficient (IL-6
 
 
 
/
 
 
 
)
mice, for instance, showed impaired acute phase protein
production and decreased high affinity immune responses
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(4, 5), while mice deficient for LIF or the IL-11 receptor 
 
 
 
subunit (IL-11R
 
 
 
1) were unable to support pregnancies
due to defective blastocyst implantation (6, 7) and decidua
formation (8, 9), respectively. This finding has been at-
tributed to partial functional redundancy between family
members due to overlapping expression patterns and the
sharing of common receptor 
 
 
 
 chains. Predictably, recep-
tor 
 
 
 
 chain deficiency resulted in more severe and global
effects. Depending on the genetic background, gp130
 
 
 
/
 
 
 
mice died in utero or shortly after birth due to myocardial
hypoplasia and reduced hemopoiesis in the fetal liver (11,
12), while the LIF receptor 
 
 
 
 chain (LIF-R
 
 
 
)
 
 
 
/
 
  
 
mice died
perinatally due to degeneration of motor neurons and as-
trocytes (10).
The LIF/IL-6 family of cytokines recruits gp130 accord-
ing to two principal mechanisms. In the case of IL-6 and
IL-11, signaling is initiated by binding to ligand-specific
receptor 
 
 
 
 subunits followed by recruitment and ho-
modimerization of two gp130 receptor 
 
 
 
 chains. In con-
trast, binding of LIF, OsM, CNTF, or cardiotrophin-1
induces the formation of 
 
 
 
 chain heterodimers consisting
of gp130 and one of the structurally and functionally re-
lated 
 
 
 
 chains, either the LIF-R
 
 
 
 or OsM receptor (1, 2).
Thus, IL-6 and IL-11 are totally dependent on gp130 for
signal transduction, while signals emanating from LIF,
OsM, CNTF, and cardiotrophin-1 may be transduced, at
least in part, by LIF-R
 
 
 
 or OsM receptor. The cytoplasmic
domains of all three 
 
 
 
 chains are characterized by con-
served modular structures with each module thought to
connect to a particular signal transduction pathway. First,
the membrane-proximal homology region associates with
cytoplasmic Jak kinases, which, upon receptor dimeriza-
tion, phosphorylate tyrosine (Y) residues within the 
 
 
 
chains (1). Second, a YxxV-phosphotyrosine motif (where
Y is followed by any two amino acids and valine [V]) at
positions Y
 
757
 
 and Y
 
769
 
 in mouse gp130 (13) and LIF-R
 
 
 
(14), respectively, is required for recruitment of the phos-
phatase src homology 2 domain–bearing protein tyrosine
phosphatase (SHP)-2, subsequent activation of the Erk mi-
togen-activated protein kinase (MAPK) and transduction of
mitogenic signals (15). Third, the membrane distal portion
of the 
 
 
 
 chains, which contain several YxxQ-phosphoty-
rosine motifs, with a glutamine (Q) in position 
 
 
 
3 relative
to Y
 
765/812/904/914
 
 of mouse gp130 and Y
 
976/996/1,023
 
 of
mouse LIF-R
 
 
 
, mediates binding and activation of the la-
tent transcription factors signal transducer and activator of
transcription (STAT)1 and STAT3 (16). This region, and
in particular the YxxQ motifs, is necessary and sufficient to
control differentiation and apoptosis of cells in vitro and to
induce acute phase proteins in cultured hepatocytes (17–
20). Moreover, the duration and intensity of the signals
emanating from gp130 and LIF-R
 
 
 
 appear to be limited by
transcriptional induction of negative regulatory proteins of
the SOCS family which impair Jak-mediated substrate
phosphorylation (21, 22).
To identify the biological responses to LIF/IL-6 cyto-
kines specifically mediated by STATs in vivo, we generated
a gp130 “knock-in” mouse containing a COOH-terminal
truncation mutation in gp130 (gp130
 
 
 
STAT
 
) which deleted
all STAT binding sites in a manner likely to be functionally
equivalent to phenylalanine substitutions (Y
 
→
 
F) in all
YxxQ motifs (17–19).
 
Materials and Methods
 
Targeting Construct and Generation of Mice.
 
A mouse genomic
129/Sv phage library was screened with a cDNA fragment en-
coding the cytosolic domain of gp130, yielding a 14-kb genomic
clone that contained the final two coding exons encompassing
amino acids 645–671 and 672–917 (13) and a 5.4 kb of 3
 
 
 
 flank-
ing sequence. PCR-mediated mutagenesis was used to introduce
the gp130
 
 
 
STAT
 
 truncation mutation by introducing the Y
 
765
 
F
(TAC to TTC), Q
 
768
 
A (CAG to GCC), and V
 
769
 
stop
 
 (GTC to
TAG) substitutions which were encoded by the oligonucleo-
tide 5
 
 
 
-TTC.AGG.CAC.GCC.TAG.G
 
A
 
C-3
 
 
 
. The newly intro-
duced 
 
stop
 
 codon was part of an AvrII site (underlined) and was
fused to the fourth nucleotide (bold A) of the 3
 
 
 
 untranslated re-
gion of the endogenous g130 gene. A cDNA encoding neomycin
resistance preceded by an internal ribosomal entry site (IRES) was
introduced into the AvrII site as a XbaI/NheI fragment, thereby
generating gp130-neo dicistronic RNA. The targeting vector also
contained 0.8 kb and 4.3 kb of sequence homologous to the final
intron and the 3
 
 
 
 flanking sequence, respectively.
From 25
 
   
 
10
 
6
 
 W9.5 embryonic stem (ES) cells (129/Sv) elec-
troporated with the SalI linearized targeting construct, 12/120
neomycin resistant colonies were correctly targeted as judged by
the hybridization pattern of BglII-digested DNA hybridized with
a genomic fragment mapping upstream of the 5
 
 
 
 end of the tar-
geting vector. Allele-specific amplification with PCR primers P1
and P2 was used to confirm the nucleotide sequence of the mu-
tated exon in the targeted allele (see Fig. 1). Two recombinant ES
cell lines (129/Sv) were injected into C57BL/6 blastocysts and
the germline chimeras were mated with C57BL/6 females. Colo-
nies homozygous for the mutation (gp130
 
 
 
STAT/
 
 
 
STAT
 
) were es-
tablished and subsequently maintained by breeding gp130
 
 
 
STAT/
 
 
 
STAT
 
 males with gp130
 
 
 
STAT/wt
 
 females, and their offspring were
routinely genotyped at weaning age by PCR analysis using prim-
ers P1 and P2 of DNA prepared from tail biopsies.
 
Synovial Cell Assays.
 
Primary cultures of synovial fibroblasts
were established by sequential collagenase digestion (collagenase
type II CLS-4, Worthington; 165 U/ml in DMEM) of clinically
normal knee joints taken from gp130
 
 
 
STAT/
 
 
 
STAT
 
 mice and their
gp130
 
wt/wt
 
 littermate controls as well as compound homozygous
SOCS-1
 
 
 
/
 
 
 
, INF-
 
 
 
 
 
/
 
 
 
 mice (23), and SOCS-1
 
 
 
/
 
 
 
; INF-
 
 
 
 
 
/
 
 
 
(24) controls were established as described previously (25). Cell
populations with the highest intensity of vascular cell adhesion
molecule 1 staining, a marker for synovial fibroblasts (26), were
maintained in DMEM supplemented with 20% FCS and assayed
at passage 5.
The mitogenic activity of mouse LIF (ESGRO; AMRAD) or
recombinant human IL-6 on synovial cells was assessed by cultur-
ing 2
 
   
 
10
 
4
 
 cells per well in 96-well plates. After serum starvation
(0.5% FCS) for 24 h, quadruplicate cultures were stimulated for
24 h with the indicated concentration of LIF or IL-6 and pulsed
for the last 4 h with 0.5 
 
 
 
Ci per well methyl-[
 
3
 
H]thymidine (Du-
pont NEN) before harvesting and measuring incorporated radio-
activity.
For transient transfection assays, 5
 
   
 
10
 
6
 
 cells were coelec-
troporated (500 
 
 
 
Farad; 270V) with 20 
 
 
 
g of a luciferase reporter
construct containing the MAPK responsive region (
 
 
 
404 to 
191
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41) of the human c-
 
fos
 
 promoter (27
 
)
 
, 20 
 
 
 
g of the Sr
 
 
 
-
 
 
 
–
galactosidase
 
 plasmid and increasing concentrations of a Flag
epitope-tagged SOCS-1 expression construct (pSOCS-1; refer-
ence 28). Cells in 24-multiwell plates were maintained in 0.5%
FCS for 48 h in the presence of IL-6 plus sIL-6R (500 ng/ml
each), saline, or FCS (10%) before lysis with 40 
 
 
 
l of reporter ly-
sis buffer (Promega). Lysates were assayed for luciferase activity
which was normalized according to the 
 
 
 
-galactosidase activity.
Expression levels from the transfected SOCS-1 plasmid were
monitored by anti-Flag immunoblotting (28).
 
Immunoblotting and In Vitro Phosphorylation Assay.
 
Serum-
starved cultures of synovial fibroblasts were stimulated with IL-6
plus sIL-6R (both at 500 ng/ml) for the indicated period of time.
1 mg of cell lysate was immunoprecipitated with an antiserum
against Jak-2 (UBI) and used for in vitro phosphorylation experi-
ments in the presence of 
 
 
 
-[
 
32
 
P]ATP as described previously (19).
SHP-2 immunoprecipitates were resolved by SDS-PAGE and
blots were probed with antiphosphotyrosine (UBI) and SHP-2
(Santa Cruz Biotechnology, Inc.) antibodies to assess protein load-
ing (19). For detection of active Erk MAPK, 50 
 
 
 
g of total cell ly-
sate were resolved by SDS-PAGE and transferred proteins were
reacted with an antibody that recognizes phosphorylated Erk1/2
(New England Biolabs, Inc.). The level of Erk protein was subse-
quently visualized by reaction with anti-Erk1/2 antibodies (Santa
Cruz Biotechnology, Inc.). STAT3 phosphorylation in tissues was
monitored after STAT3 immunoprecipitation (Santa Cruz Bio-
technology, Inc.) of 2 mg of tissue lysate obtained from mice 20
min after a single intravenous injection of either 5 
 
 
 
g IL-6, LIF,
IL-11, or saline and detection with antiphosphotyrosine and anti-
STAT3 (Transduction Laboratories) antibodies, respectively (19).
 
Northern Blot Analysis.
 
Poly(A)
 
 
 
 RNA was prepared from
livers of mice 40 min (for SOCS induction) or 4 h (for acute
phase protein) after a single intravenous injection of 5 
 
 
 
g of LIF,
IL-6, or saline according to standard protocols. Poly(A)
 
 
 
 RNA
was also isolated from cultures of primary synovial cells stimulated
with IL-6 plus sIL-6R (both at 500 ng/ml) for 45 and 180 min,
respectively. 3 
 
 
 
g of poly(A)  RNA were hybridized with
cDNAs encoding either cytokine-inducible src homology 2 pro-
tein (CIS), SOCS-1, SOCS-2, or SOCS-3, gp130 or neomy-
cin, and serum amyloid A or haptoglobin. All RNA blots were
finally hybridized for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) to assess the amounts of RNA analyzed.
Clinical Assessment and Histology. For each limb, clinical
scores were allocated for erythema, swelling, and flexibility of
joints twice per week for up to 25 wk as described previously
(29). The scoring system for each limb was as follows: 0, normal;
1, moderately affected; and 2, severely affected. Soft tissues were
fixed in formalin for 24 h, while joints were fixed in 10% forma-
lin for 48 h, decalcified, and embedded in paraffin (29). Sections
were stained with hematoxylin and eosin. Histopathological fea-
tures associated with the large appendicular joints (shoulder, el-
bow, wrist, hip, knee, ankle) were scored as 0, normal; 1, minor
synovial changes without degenerative alterations or cartilage
metaplasia; 2, mild degenerative joint disease with cartilage de-
posits with or without synovial hyperplasia; and 3, severe degen-
erative joint disease with marked cartilage metaplasia with or
Figure 1. Generation of gp130 STAT/ STAT mice. (A) Targeting strategy for the introduction of the gp130 STAT truncation. The cytoplasmic domain of
mouse gp130 with its homology motifs Box1, Box2, and Box3 (black) are schematically depicted alongside the corresponding genomic structure with
exons numbered according to Betz et al. (reference 31). The targeting vector contains a Y765RHQ768 to FRHA substitution and a translational stop codon
at position 769 preceding a ribosomal reentry site and the sequence encoding neomycin resistance (IRESneo). A diagnostic digest with BglII (Bg) yields a
fragment of 3.8 kb from the wt allele and a 5.6-kb fragment from the targeted allele when hybridized with a probe external to the targeting vector (*). P1
and P2 refer to primers used for an allele-specific PCR reaction. S, SalI. (B) Southern blot analysis of BglII digests of DNA prepared from a targeted ES
cell line and tail biopsies obtained from offspring of gp130 STAT/wt intercrosses. The immobilized DNA was hybridized with a probe (* in A) external to
the targeting construct. (C) Northern blot analysis of liver RNA extracted from offspring of gp130 STAT/wt matings. Poly(A)  RNA was hybridized with
a cDNA fragment encoding the extracellular portion of gp130. Dicistronic gp130 STAT-neo mRNA transcripts were  1.4 kb larger than the two major
wt gp130 mRNA species. The same blot was stripped and reprobed for expression of the neo gene.192 Degenerative Joint Disease and Intestinal Ulceration in gp130 Mutant Mice
without synovial hyperplasia. All clinical and histological assess-
ments were performed blind.
Immunization, ELISA, and Immunohistochemistry. Mice were
immunized by injecting  1  l of OVA, (1 mg/ml in PBS, pH
7.4, emulsified with Freund’s Complete Adjuvant) into each
Peyer’s patch (30). Mice were boosted intraduodenally 14 d later
with OVA and euthanized 5 d after the secondary challenge. The
proteinacious fraction of fecal pellets, obtained from intestinal
washes, was prepared as described previously (30) and the small
intestine was collected, fixed in cold ethanol, embedded in paraf-
fin, and sectioned (5  m) for immunohistochemistry of OVA-
containing cells (5). OVA-specific ELISA assays were carried out
for IgA, IgG, and IgM using Ig-specific biotin conjugated goat
anti–mouse antibodies (Zymed Laboratories). Total isotype-spe-
cific Ig levels in sera of unchallenged mice were determined by
ELISA using commercially available kits according to the manu-
facturer’s recommendations (Bethyl Laboratories, Inc.).
Embryo Cross-Fostering. Blastocysts were flushed from uteri on
day 4 of gestation (day 1 is day of plug) and transferred to day 3
pseudopregnant recipients as described previously (6). All offspring
were genotyped by Southern blotting of DNA from tail biopsies.
Results
To inactivate the four YxxQ STAT-binding sites in gp130
at positions Y765/812/904/914, we replaced exon 18, encoding
amino acids 672–917, with a version truncated at the
COOH-terminal side of amino acid 768 and containing
the Y765F and Q768A substitutions. After homologous re-
combination in ES cells, the presence of the expected mu-
tations was confirmed by sequencing allele-specific PCR
amplicons generated from the targeted gp130 allele with
primers P1 and P2 (Fig. 1 A). Transcription of the mutated
gp130 allele generated a dicistronic gp130-neo mRNA
species  1.4 kb larger than wild-type (wt) gp130 mRNA
which encoded a truncated gp130 STAT protein (Fig. 1 C).
Interbreeding of gp130 STAT/wt mice yielded homozygous
offspring close to the expected Mendelian ratio (Fig. 1 B
and Table I). However, subsequent matings of gp130 STAT/wt
females with gp130 STAT/ STAT males yielded significantly
fewer gp130 STAT/ STAT than gp130 STAT/wt offspring at
weaning age (Table I), although mice of the two genotypes
were recovered at equal ratios during embryonic develop-
ment (E18, and data not shown). At birth, gp130 STAT/
 STAT mice appeared superficially healthy, but in com-
parison to gp130wt/wt and gp130 STAT/wt littermates, they
showed a 20–30% reduction in body weight (1.93 g  
0.38 g vs. 2.93 g   0.12 g; P   0.05, n   20) and trunk
length, which persisted throughout adulthood. The average
life span of gp130 STAT/ STAT mice was reduced (6   1
mo for males, 8    2 mo for females) compared with
gp130 STAT/wt littermates (15   2 mo for both sexes) which
were indistinguishable from gp130wt/wt mice in all aspects
analyzed.
Table I. Reproductive Frequency in gp130 Mutant Mice
Malea Female Live pups
wt/  (17) wt/  (17) wt/wt (66) 
wt/  (156)
 /  (57)
 /  (47) wt/  (47) wt/  (328)b
 /  (179)b, c
wt/  (15)  /   (6) wt/  (0)
 /  (0)
 /  (8)  /   (3)  /  (0)
Maled Female
Numbers of
blastocysts transferred Foster mother Live pups
wt/   /  (2) 28 wt/wt (2) wt/  (4)
 /  (5)
wt/  wt/wt (5) 28  /  (3) wt/wt (0)
wt/  (0)
wt/  wt/wt (5)
29
wt/wt (3) wt/wt (5)
wt/  (3)
aTest breeding of gp130 mice of the indicated genotypes. All parents and offspring were genotyped by PCR analysis of DNA from tail biopsies.
Each gp130 STAT/ STAT female was test mated at least twice with a male of proven fertility. Number of animals is indicated in parentheses.
b67 pups in total were cannibalized by their mothers before genotyping.
cP   0.001 when compared with the expected 1:1 ratio between genotypes (chi-squared analysis).
dTransfer of blastocysts into pseudopregnant recipient mice. Blastocysts were flushed from the uteri on day 4 of gestation and transferred to day 3
pseudopregnant recipients. Numbers of animals in indicated in parentheses.
 / ,  /wt, and wt/wt refers to gp130 STAT/ STAT, gp130 STAT/wt, and gp130wt/wt mice, respectively.193 Ernst et al.
Failure of Uterine Implantation and Hepatic Acute Phase Re-
sponse. While gp130 STAT/ STAT male mice sired litters of
equal size to those of gp130 STAT/wt or wt males, female
gp130 STAT/ STAT mice mated with males of any genotype
showed no external signs of pregnancy (Table I). Histolog-
ical analysis of uteri from gp130 STAT/ STAT mice 5.5 d after
coitum revealed the presence of blastocysts that showed no
overt signs of implantation at a time when embryos in uteri
of gp130 STAT/wt and gp130wt/wt mice had implanted and
were surrounded by the secondary decidua (Fig. 2 A).
However, blastocysts of all genotypes recovered from
gp130 STAT/ STAT mice developed to term when surgically
transferred to day 3 pseudopregnant wt recipient mice,
while again no signs of pregnancy were observed when
transferred to gp130 STAT/ STAT recipient mice (Table I).
These results unequivocally show a maternal defect at the
time of embryo implantation that is strikingly similar to the
defect described in mice deficient for LIF (6, 7).
To determine whether impaired STAT signaling in the
uteri of gp130 STAT/ STAT mice was the likely reason for the
failure of blastocyst implantation and subsequent decidua
formation, we monitored STAT3 phosphorylation in the
liver and uterus after single bolus injections of IL-6, IL-
11, or LIF. In both tissues, STAT3 phosphorylation in
gp130 STAT/ STAT mice was markedly reduced in response
to LIF and completely abrogated in response to IL-6 or IL-
11, compared with identically treated heterozygous control
mice (Fig. 2, B and D). This observation was further pur-
sued in liver by measuring the induction of hepatic class I
acute phase genes which are regarded as classical STAT-
mediated responses (20). Induction of serum amyloid A
and haptoglobin mRNAs in gp130 STAT/ STAT mice was
Figure 2. Failure of blastocyst implantation due to impaired signaling
through heterodimeric gp130 STAT/LIF-R  complexes. (A) Histological
sections through the uteri from a gp130 STAT/wt and gp130 STAT/ STAT
mouse 5.5 d after coitum. The blastocyst (white arrowhead) in the
gp130 STAT/ STAT uterus showed no signs of implantation. In contrast,
the developing embryo is surrounded by stromal cells forming the sec-
ondary decidua (white arrow) beneath the epithelial lining (black arrow-
head) of the gp130 STAT/wt uterus. (B) Tyrosine phosphorylation (pY) of
STAT3 immunoprecipitates prepared from liver of gp130 STAT/wt control
and gp130 STAT/ STAT mutant mice 20 min after a single intraperitoneal
injection of 5  g of IL-6 (6), IL-11 (11), LIF (L), or saline (s). The mem-
branes were reprobed for STAT3 to assess equality of protein loading.
Note occasional appearance of a nonspecific band above STAT3. (C)
Steady-state levels of mRNA for hepatic type I acute phase proteins ex-
tracted from livers of mice as in B. 3  g of poly(A)  RNA were hybrid-
ized with radiolabeled full length cDNAs encoding human serum amy-
loid A (SAA) or haptoglobin (Ha-globin). Ethidium bromide (EtBr) stain
of the gels revealed similar amounts of RNA analyzed. (D) Tyrosine
phosphorylation (pY) of STAT3 immunoprecipitates prepared from uteri
of mice treated as in B. The membranes were reprobed for STAT3 to as-
sess equality of protein loading.194 Degenerative Joint Disease and Intestinal Ulceration in gp130 Mutant Mice
clearly diminished in response to LIF and absent in re-
sponse to IL-6 (Fig. 2 C). Collectively, these results suggest
that the mutant receptor   chain heterodimers between
gp130 STAT and LIF-R  (which retains the 3 YxxQ motifs
in LIF-R ) induced by LIF, while less efficient than a wt
gp130/LIF-R  complex containing 7 YxxQ motifs, re-
tains some STAT-mediated signaling capacity. Meanwhile
homodimers formed between two truncated gp130 STAT
proteins in response to IL-6 and IL-11 failed to promote
STAT-mediated signaling.
Gastrointestinal Ulceration and Impaired Humoral and Muco-
sal Immunity. Under specific pathogen–free conditions,
approximately half of all gp130 STAT/ STAT mice of 4 mo of
age showed occult traces of fecal blood and ulceration of the
gastric pylorus (Fig. 3 a). We also observed ulceration of the
anorectal region which was invariably associated with rectal
prolapse. Notably, the ulceration at both sites was confined
to the vicinity of the sphincters suggesting defective epithe-
lial repair in response to sustained mucosal injury. Mutant
mice kept under conventional conditions also developed
caecal ulcers (41%; Fig. 3 b) and acute inflammation at addi-
tional mucosal sites including the conjunctivae (41%) and
the nasolacrimal ducts (29%). Furthermore, in comparison to
gp130 STAT/wt mice, gp130 STAT/ STAT mice showed a much
higher load of Giardia muris which is an endemic parasite in
the conventional facility in which the mice were housed.
Figure 3. Gastrointestinal ulceration and impaired im-
munity in gp130 STAT/ STAT mice. Mucosal ulcers (arrow-
heads) in the gastric pylorius (a) and caecum (b). High
magnification (insert) shows surface ulcer debris, neutro-
phil-rich inflammatory exudates, and regenerative changes
in adjacent epithelial cells. S, stomach; D, duodenum. (c
and d) Appearance of OVA-containing plasma cells in the
lamina propria of small intestinal villi in gp130 STAT/wt
control (c) and gp130 STAT/ STAT mutant (d) mice detected
by FITC-mediated immunofluorescence of anti-OVA an-
tibodies. (e) Isotype-specific anti-OVA antibody response
in extracts of fecal pellets and serum of gp130 STAT/ STAT
mutant and gp130 STAT/wt control mice. Mice were immu-
nized by injection of OVA directly into Peyer’s patches
and boosted with OVA 14 d later. OVA-specific Ig levels
were determined after a further 5 d as described in Materi-
als and Methods. Mean   SEM, n   7. (f) Number of
OVA-specific plasma cells in the small intestine, spleen,
and mesenteric lymph nodes (MLN) of mice used for the
experiment in Fig. 2 E. Data were obtained by immuno-
fluorescent histology with FITC-conjugated goat–anti
mouse heavy chain reagent and represent the mean  
SEM in 30–50 randomly selected high power fields per
mouse with four mice per group.195 Ernst et al.
Since IL-6 is required for differentiation of B cells to
high affinity IgA- and IgG-producing plasma cells (4, 5,
31), we sought to determine mucosal immune responses of
gp130 STAT/ STAT mice. In the absence of deliberate immu-
nization and compared with heterozygous controls, mutant
mice showed reduced levels of circulating IgA (gp130 STAT/
 STAT, 0.62   0.05 mg/ml, n   7 vs. gp130 STAT/wt mice,
0.85   0.10 mg/ml, n   6), IgG1 (0.17   0.07 mg/ml
vs. 0.35   0.11 mg/ml), IgG2a (0.18   0.13 mg/ml vs.
0.53   0.12 mg/ml), and IgG2b (0.38   0.15 mg/ml vs.
0.87   0.17 mg/ml). In contrast, the levels of circulating
IgM were similar for mice of both genotypes. The capacity
of gp130 STAT/ STAT mice to mount a specific intestinal IgA
response after local immunization of Peyer’s patches with
OVA was grossly impaired when assessed by OVA-specific
Ig isotype level in fecal pellets and serum (Fig. 3 e). Simi-
larly, the OVA-specific IgG response in the intestine was
also reduced and there were significantly less anti-OVA–
containing cells in the small intestine (Fig. 3, c and d), mes-
enteric lymph nodes, and spleen of gp130 STAT/ STAT mice
(Fig.3 f) reminiscent of the findings reported previously in
IL-6–deficient mice (30). Collectively, these data imply that
gp130 transduces the IL-6–mediated final maturation of B
cells to high affinity Ig-secreting plasma cells via its STAT-
binding sites in the COOH-terminal domain.
Severe Degenerative Joint Disease in gp130 STAT/ STAT
Mice. Unexpectedly, swelling of one or more of the large
weight-bearing joints was observed in 60% of adult
gp130 STAT/ STAT mice (n   49, mean age 89 d ranging
from 56–412 d), which resulted in flexion deformities of
the hind limbs and reluctance of the mice to stand (Fig. 4, a
and b). Joints of gp130 STAT/ STAT mice were often affected
bilaterally but only rarely showed signs of erythema. Sys-
tematic clinical assessment showed that all gp130 STAT/
 STAT mice showed stiffness of one or more limbs with re-
stricted flexion and extension of the ankles as well as dorsi-
flexion at the wrist joints (Fig. 4 b to e). Notably, some de-
gree of joint restriction was already evident in one or more
limbs of P7-neonatal gp130 STAT/ STAT mice but did not
increase significantly with age and only rarely affected pre-
viously healthy joints (Table II). By contrast, none of the
gp130 STAT/wt control mice showed any clinical evidence
Figure 4. Clinical assessment of the joint disease in
gp130 STAT/ STAT mice. Swollen ankle joints and char-
acteristic flexion deformities of hind legs in bilaterally
affected gp130 STAT/ STAT mice (a). The restriction of
ankle movement (b and c) and fixed flexion deforma-
tion of front paws (d and e) were consistent findings in
gp130 STAT/ STAT mice but were never seen in
gp130 STAT/wt littermates.196 Degenerative Joint Disease and Intestinal Ulceration in gp130 Mutant Mice
of swelling or restricted joint movement at any age. Abnor-
mal joints were also observed in gp130 STAT/ STAT mice
maintained under specific pathogen–free conditions, indi-
cating that this pathology was unlikely to be secondary to
infections at mucosal sites.
The joints of 49 clinically affected mice were examined
histologically and graded as described in Materials and
Methods. Of the 292 large appendicular joints examined (16
hips, 75 knees, 67 ankles, 40 shoulders, 50 elbows, 44
wrists), 76% were scored as 0 or 1 while 24% were graded as
2 or 3. Curiously, joints showing degenerative changes
(grade 2 or 3) were twice as common in male (27.8%, n  
65) than female (15.1%, n   8) gp130 STAT/ STAT mice. His-
tologically, these joints showed cartilaginous nodules along
the joint capsule extending from the edge of the articular
cartilage. In the knee joints, these nodules invariably re-
placed the menisci and supporting connective tissue (Fig. 5,
a and b) and occasionally the joint spaces contained dis-
lodged and rounded cartilaginous nodules (Fig. 5 e). These
changes were often accompanied by enlargement and defor-
mation of the joints which occasionally affected the growth
plate (Fig. 5 b). In addition, joints of older gp130 STAT/ STAT
mice often showed erosion of the articular surface and mild
synovial hyperplasia associated with the tendon sheaths and
nonswollen joints. Since histological examination of clini-
cally affected joints of newborns revealed considerable
structural variability, we were unable to unambiguously as-
cribe histological abnormalities to these joints. However, no
primary irregularities were detected in the growth plate of
young adult gp130 STAT/ STAT mice. Occasionally, marked
synovial hyperplasia was observed in the recesses of the joint
cavities with expansion of the subsynovial connective tissue
adjacent to the articular surfaces (Fig. 5, c and d). However,
foci of metaplastic cartilage were rarely observed within this
de novo–formed connective tissues suggesting that the carti-
laginous nodules were composed of newly formed cartilage
and not disordered menisci or articular cartilage. Inflamma-
tory cells, primarily lymphocytes and macrophages, were
present in low numbers in the synovium and subsynovial
tissues of pathological joints; however, neutrophils were
usually absent. Collectively, these observations suggest that
the joint pathology in gp130 STAT/ STAT mice was primarily
a result of synovial hyperplasia with progressive chronic in-
flammation and secondary cartilaginous metaplasia restrict-
ing joint movement and culminating in the degeneration of
the articular cartilage of the major weight-bearing joints in
older mice (Fig. 5, f and g).
Enhanced Mitogenic Response of Synovial Fibroblasts to IL-6.
Since the LIF/IL-6 family cytokines have been implicated
in promoting synovial hyperplasia (32, 33), we investigated
whether altered signaling through gp130 STAT receptors
affected the mitogenic response of mutant synovial cells
Table II. Clinical Assessment of Joint Stiffness in gp130 STAT/STAT Mice
Age (d) 30 50 71 98 141 176
Limb
Mouse 1 Rear left 1 1 1 1 2 2
Rear right 1 1 1 1 1 1
Front left 0 0 0 0 0 0
Front right 2 2 2 2 2 2
Mouse 2 Rear left 1 1 1 1 2 2
Rear right 1 1 1 1 1 1
Front left 0 0 0 1 1 1
Front right 0 0 0 1 1 1
Mouse 3 Rear left 1 1 0 1 1 2
Rear right 1 1 1 2 1 1
Front left 0 0 0 0 0 0
Front right 0 0 0 0 0 0
Average score per gp130 STAT/STAT mouse (n   14) 3.3   1.2 2.9   1.7 3.0   1.2 3.3   1.2 3.5   1 3.5   1.1
Average score per gp130 STAT/wt mouse (n   21) 0 0 0 0 0 0
Mice were clinically assessed and scores for joint movement were allocated as described in Materials and Methods. Each limb of mice in cohorts of
gp130 STAT/ STAT and gp130 STAT/wt animals was assessed twice per week for restriction in wrist and ankle movement as illustrated in Fig. 4 c to f.
Scores were allocated for: 0, no restriction; 1, moderate restriction; and 2, severe restriction, with 8 being the maximal score per mouse. None of the
gp130 STAT/wt control mice scored positive at any time point. The table shows the results for selected time points of three representative gp130 STAT/
 STAT mice and the average score per mouse in the mutant cohort (mean   SD, n   14).197 Ernst et al.
in vitro. Primary cultures of synovial fibroblasts, derived
from clinically unaffected knees of gp130 STAT/ STAT mice,
showed an enhanced rate of [3H]thymidine incorporation
in response to IL-6 or LIF when compared with cells ob-
tained from gp130wt/wt mice (Fig. 6 A). Furthermore,
mutant cells responded to 100- to 1,000-fold lower con-
centrations of cytokines than wt cells and showed sustained
IL-6–dependent activation of gp130-mediated signaling, as
demonstrated by autophosphorylation of Jak-2, tyrosine
phosphorylation of SHP-2, and phosphorylation of MAPK
isoforms Erk1/2 (Fig. 6 B). These in vitro data indicate in-
creased sensitivity and proliferative response of mutant sy-
novial fibroblasts to IL-6 associated with sustained gp130
signaling through the SHP-2/ras/Erk pathway.
Sustained Activation of the SHP-2/ras/Erk Pathway Results
from Impaired Induction of SOCS-1. One possible mecha-
nism accounting for sustained activation of the SHP-2/
ras/Erk pathway in response to IL-6 could be that
impaired STAT activation retarded the termination of
gp130-mediated signaling. We hypothesized that this
might result from impaired induction of SOCS/CIS fam-
ily gene expression (21, 22). As depicted in Fig. 7 A, the
expression of CIS, SOCS-1, SOCS-2, and SOCS-3
mRNA were readily induced in the livers of wt mice af-
ter a single injection of either IL-6 or LIF. IL-6 treatment
also induced CIS and SOCS-2 mRNA in the livers of
gp130 STAT/ STAT mice, however, we observed almost
complete absence of SOCS-1 mRNA induction and re-
Figure 5. Histological assess-
ment of joint disease in
gp130 STAT/ STAT mice. Sagittal
sections of knees of age-matched
71-d-old gp130 STAT/wt  control
(a) and gp130 STAT/ STAT mutant
mice (b). The section of the mu-
tant knee shows enlargement of
the synovial space (*), synovial
hyperplasia and pannus forma-
tion (black arrowhead), cartilagi-
nous overgrowth in the menicsi
(white arrowhead), and destruc-
tion and deformation of the ar-
ticular surfaces. Note that the
cartilaginous metaplasia on the
head of the femur (arrow) is as-
sociated with alterations of the
growth plate. The shoulder (c)
joint of gp130 STAT/ STAT mouse
illustrates the early stage mani-
fested as enlargement of the syn-
ovial space (*), prominent syn-
ovial hyperplasia (arrowheads),
exuberant pannus formation
with early cartilaginous metapla-
sia (arrows) but little destruction
of the articular surface. A high
magnification (d) of the area
boxed in c shows synovial hy-
perplasia in the recess of the cav-
ity of the shoulder joint. The
metaplastic cartilage deposits
within the synovial cavity (e)
contain disorganized clusters
of chondrocytes (arrowhead)
which occupy lacunae within
the matrix and contrast the orga-
nized appearance of smaller
chondrocytes in “columns” in
normal articular cartilage (ar-
row); Safranin-O and Alcian
Blue stain proteoglycan red and
mineralized matrix blue, respec-
tively. Frontal sections through
knees from 180-d-old gp130  wt
(f) and gp130    mice (g) docu-
ment the expanded synovial
space (*), destruction, and ero-
sion of the articular cartilage (aC
arrowhead). aC, articular carti-
lage; F, femur; H, humerus; M,
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duced SOCS-3 mRNA induction. Notably, the induction
of SOCS-1 mRNA was also markedly reduced in synovial
cells from gp130 STAT/ STAT mice compared with cells
from wt mice (Fig. 7 B). These data support previous ob-
servations suggesting that IL-6–dependent activation of
SOCS-1 and SOCS-3 genes is mediated, at least in part,
by STATs (34). The reduced induction of SOCS-1
mRNA observed in the livers of LIF-treated gp130 STAT/
 STAT mice (Fig. 7 A) most likely resulted from diminished
STAT signaling through the less effective gp130 STAT/
LIF-R  heterodimers.
To explore the concept of enhanced gp130-mediated
SHP-2/ras/Erk signaling in the absence of SOCS-1, we
analyzed IL-6-signaling in SOCS-1–deficient synovial cells.
These cells were derived from adult SOCS-1 /  mice es-
tablished on an IFN- –null background to rescue the peri-
natal lethality associated with SOCS-1 deficiency (23). As
revealed in Fig. 8 A, compound mutant SOCS-1 / , IFN-
  /  cells, like gp130 STAT/ STAT cells, showed enhanced
[3H]thymidine incorporation in response to nanomolar
concentrations of IL-6, compared with cells prepared from
control mice of the corresponding genetic background
(SOCS-1 / , IFN-  / , and gp130 STAT/wt, respectively).
Compared with SOCS-1 /  IFN-  /  control cells, we
also observed sustained IL-6–mediated Erk1/2 phosphory-
lation in SOCS-1 /  IFN-  /  cells (Fig. 8 B). Thus, the
enhanced proliferative responsiveness to IL-6 was also a
feature of SOCS-1 /  IFN-  /  cells, however, this was
less marked than in gp130 STAT/ STAT cells.
If impaired or reduced induction of SOCS-1 (and
SOCS-3) expression accounted for sustained activation of
the Jak/SHP-2/ras/Erk cascade in response to IL-6 in
gp130 STAT/ STAT synovial cells, then overexpression of
SOCS-1 should revert the hyperresponsive phenotype of
Figure 6. Hyperresponsiveness of synovial cells correlates with sus-
tained Erk MAPK activation. (A) [3H]thymidine incorporation by sy-
novial cells prepared from wt and gp130 STAT/ STAT mice and stimulated
with LIF or IL-6. Cells derived from clinically unaffected joints were
stimulated for 24 h with the indicated concentration of LIF or IL-6 in the
presence of sIL-6R (500 ng/ml). Each point represents the mean   SD.
*P   0.05 compared with unstimulated cultures of the same genotype.
(B) Activation of intermediate signaling molecules in synovial cells stimu-
lated with IL-6 and sIL-6R (both at 500 ng/ml) for the indicated period
of time. Cell lysates were immunoprecipitated with either a Jak-2 antise-
rum and incubated with  -[32P]ATP to assess Jak-2 autophosphorylation,
or with a SHP-2 antiserum and blotted with antiphosphotyrosine anti-
bodies. Erk MAPK activation was analyzed by directly probing lysates
with an antibody specific for phospho-Erk1/2 (Erk-P). The total amount
of SHP-2 and Erk proteins was assessed by reprobing the membranes for
SHP-2 and Erk1/2, respectively.
Figure 7. Impaired induction of SOCS mRNA in response to signal-
ing through gp130 STAT. (A) SOCS/CIS mRNA steady-state levels after
cytokine stimulation in vivo. Northern blot analysis of poly(A)  RNA
extracted from livers of gp130 STAT/ STAT and wt mice 40 min after a sin-
gle intravenous injection of 5  g of LIF, IL-6, or saline. Blots were se-
quentially probed for SOCS-1, SOCS-2, SOCS-3, CIS, and finally
GAPDH to assess for amounts of RNA analyzed. (B) Induction of
SOCS-1 and SOCS-3 mRNA steady-state levels in synovial cells stimu-
lated with IL-6 and sIL-6R for the indicated period of time. Northern
blots analysis of poly(A)  RNA probed for SOCS-1, SOCS-3, and
GAPDH to assess for amounts of RNA analyzed.199 Ernst et al.
these cells. To explore this notion, we exploited the fact
that the minimal c-fos promoter is activated through the
ras/Erk pathway (27). As expected, IL-6 stimulation of
gp130 STAT/ STAT cells, transiently transfected with a c-fos-
luciferase reporter construct, yielded higher luciferase ac-
tivity than IL-6 stimulation of wt cells (Fig. 8 C). Further-
more, increasing the cellular concentration of SOCS-1
protein, after cotransfection with an epitope tagged SOCS-
1Flag expression plasmid (pSOCS-1), reduced IL-6-respon-
siveness in gp130 STAT/ STAT cells to levels observed in wt
cells. Finally, a complete block of IL-6–mediated luciferase
activity in gp130 STAT/ STAT cells required greater amounts
of transfected pSOCS-1 protein than in wt cells. Collec-
tively, these observations are consistent with the notion
that elevated levels of recombinant SOCS-1Flag protein
were required to terminate IL-6 signaling in gp130 STAT/
 STAT mutant cells to compensate for impaired induction of
endogenous SOCS-1 and SOCS-3 expression. Since re-
combinant SOCS-1Flag expression did not suppress c-fos-
luciferase activity induced by serum, overexpression of
SOCS-1Flag was not directly interfering with activity of the
c-fos-luciferase reporter plasmid.
Taken together, these data strongly suggest that the hy-
perresponsiveness of synovial cells from gp130 STAT/ STAT
mice arose from defective or impaired STAT-mediated
SOCS induction which resulted in sustained activation of
the SHP-2/ras/Erk pathway, leading to synovial hyperpro-
liferation and cartilaginous metaplasia and ultimately the
degeneration of the joint.
Discussion
At the molecular level, the multiple and tissue-specific
activities of cytokines are explained, in part, by activation
of multiple signaling cascades emanating from discrete in-
tracellular receptor domains which regulate distinct (sets of)
target genes. While complete inactivation of multidomain
receptors will result in phenotypes reflecting inactivation of
all associated signaling pathways, the selective deletion of
one particular domain provides the opportunity to associate
a specific signaling cascade with a particular physiological
or pathological process. Here we used a knock-in strategy
to mimic the effect of a nonsense mutation that specifically
deletes the COOH-terminal domain of gp130, along with
its associated STAT activation sites, but still permits activa-
tion of the SHP-2/ras/Erk pathway (15, 19). Consequently,
the phenotype in gp130 STAT/ STAT mice is largely a direct
consequence of the absence (in the case of gp130 STAT ho-
modimerization) or diminution (in the case of LIF-R /
gp130 STAT heterodimerization) of STAT-mediated cellu-
lar responses. Furthermore, we also identified the impor-
tance of STAT signals in promoting inhibitory feedback
signals on gp130 and the associated SHP-2/ras/Erk path-
way, thereby reinforcing a concept that the two pathways
are under reciprocal negative control (35).
The phenotypes of mice with gp130 impairment muta-
tions affecting either the STAT (gp130 STAT/ STAT mice
reported here) or the SHP-2/ras/Erk signaling cascade
(gp130757F/757F mice; reference 35) are dramatically differ-
ent from the myocardial hypoplasia and associated embry-
Figure 8. Impaired SOCS induction enhances IL-6 and LIF responsiveness. (A) Mitogenic hy-
perresponsiveness of SOCS-1–deficient synovial cells to IL-6. [3H]thymidine incorporation assays
were carried out on primary cultures of syonvial cells, derived from mice of the indicated genotype,
in the presence of the indicated concentration of IL-6 and sIL-6R (500 ng/ml) as described in the
legend to Fig. 5 a. Each point represents the mean   SD. *P   0.05 compared with unstimulated
cultures of the same genotype. (B) SOCS-1–deficient cells show sustained activation of Erk1/2 in
response to IL-6. Erk MAPK phosphorylation assay of synovial fibroblasts stimulated for the indi-
cated time with IL-6 and sIL-6R (both at 500 ng/ml) as described in Fig. 5 b. Erk1/2-P indicates
the phosphorylated isoforms of Erk1 and Erk2. The total amount of Erk protein was assessed by
reprobing the membranes for Erk1/2. (C) Hyperresponsiveness of synovial cells to IL-6 is corrected
by overexpressing SOCS-1. Synovial cells were transiently transfected with a fos-luc reporter con-
struct, the Sr - -gal control plasmid and increasing concentrations of a Flag-epitope tagged SOCS-1
(pSOCS-1) expression construct, stimulated for 48 h with human IL-6 plus sIL-6R (both at 500
ng/ml) or 10% FCS as a positive control. Luciferase activity was normalized by reference to
 -galactosidase activity and is expressed as fold induction over unstimulated cultures. The level of
SOCS-1Flag protein was assessed at the end of the experiment by immunoprecipitation and Western
blotting using anti-Flag antibodies. Each point represents the mean   SD.200 Degenerative Joint Disease and Intestinal Ulceration in gp130 Mutant Mice
onic lethality observed in gp130 /  mice (11). Similarly,
no profound effects on embryonic development were re-
ported in gp130FxxQ/FxxQ mice, where STAT signaling was
abolished after replacement of the cytoplasmic domain of
gp130 with a human cDNA encoding phenylalanine sub-
stitutions in all YxxQ motifs (36). However, the latter
mutation resulted in perinatal death associated with the ap-
parent failure of milk uptake and perturbed CNTF-medi-
ated astrocyte differentiation (35). Since the phenotype of
gp130FxxQ/FxxQ mice is somewhat reminiscent of that ob-
served in LIF-R  /  (10) and CNTF-R  /  mice (36),
but entirely different to that associated with IL-6 /  (4, 5)
or IL-11R 1 /  mice (8, 9), signaling through the het-
erodimeric LIF-R /gp130 rather than through homo-
dimeric gp130 appears critical after birth. Therefore, it
is likely that STAT signaling through LIF-R /gp130FxxQ
receptor heterodimers is rate limiting in gp130FxxQ/FxxQ
mice, while signaling through LIF-R /gp130 STAT het-
erodimers, although decreased when compared with wt
LIF-R /gp130 dimers, reaches the threshold that enables
postnatal survival of most of the gp130 STAT/ STAT pups.
The “magnitude” of the STAT signal may be influenced
by the rate of internalization of ligand occupied LIF-R /
gp130 complexes, which in turn is determined by the col-
lective activity of individual dileucine internalization signals
(L1064I in LIF-R  and L984L in gp130; references 37 and
38). Thus, one could speculate that LIF-R /gp130FxxQ
dimers are more efficiently internalized than LIF-R /
gp130 STAT dimers, and thus signal from the LIF-R /
gp130 STAT dimers may be sustained for longer.
Degenerative Joint Disease in gp130 STAT/ STAT Mice.
The most striking observation in gp130 STAT/ STAT mice
was restricted joint movement which was apparent from an
early age and consistently affected older mice albeit with
variable severity. While early stages of the joint disease bear
hallmarks of inflammation, the intermediate stages were
reminiscent of rheumatoid arthritis with the overgrowing
pannus-like tissue at the edge of the articular surface. Like-
wise, the formation of cartilage in these pannus-like tissues
resembled osteoarthritis in which cartilaginous and osseous
osteophytes formed along the rim of the eroded cartilage
plate. The advanced stage with its overgrowth of cartilage
along the synovial lining, however, resembled neither pa-
thology but rather the rare human condition synovial
chondromatosis (39), although the characteristic multiple
“loose” bodies of hyaline cartilage within the joint space
were only infrequently observed in gp130 STAT/ STAT mice.
Many studies have implicated the LIF/IL-6 family cy-
tokines and their soluble receptors as proinflammatory mi-
togens for synovial fibroblasts in inflammatory joint diseases
including rheumatoid arthritis (32, 33). Our model, in
which signaling through gp130 STAT resulted in impaired
or reduced induction of SOCS-1 and SOCS-3, implicates
activation of the SHP-2/ras/Erk pathway as the likely mo-
lecular mechanism promoting hyperproliferation of syn-
ovial cells by increasing their sensitivity to physiological
levels of LIF/IL-6 cytokines. In turn, the hypersensitivity
of these cells may trigger a sequence of changes including
chronic synovitis that results in cartilaginous metaplasia and
culminates in a degenerative process affecting the major
weight-bearing joints. However, we cannot categorically
exclude the possibility that synovial hyperplasia and the for-
mation of exogenous cartilage occurred independently of
each other.
Since our data provide strong genetic evidence for a crit-
ical involvement of gp130, STAT, and SOCS proteins in
maintaining the integrity of joints of the appendicular skel-
eton, why do other mouse strains with mutations in either
the LIF/IL-6 cytokine signaling cascade or in SOCS genes
lack overt joint pathology? This apparent anomaly can be
explained by extrapolating from observations by Ohtani et
al. (35) who showed that the gp130-dependent STAT and
SHP-2/ras/Erk pathways play reciprocal roles in the im-
mune response by providing a balance between positive
and negative signals. This delicate balance between the two
pathways at the level of gp130 is further emphasized
through their reciprocal negative regulation (35, 40, 41).
Hence, balanced alterations of the signaling output from
gp130-dependent STAT and SHP-2/ras/Erk pathways, ei-
ther by attenuation (for instance in ligand and receptor null
mutants) or augmentation (for instance in mice transgenic
for the ligands), resulted in a number of phenotypes which
were not observed in mice with an imbalance between
the two pathways (for instance in gp130 STAT/ STAT or
gp130757F/757F mice; reference 35). Similarly, the simulta-
neous and sustained activation of the SHP-2/ras/Erk and
STAT pathways in response to IL-6 in synovial cells from
SOCS-1 /  IFN-  /  compound mice did not result
in cartilaginous overgrowth or destruction of the large
weight-bearing joints. However, SOCS-1 /  IFN-  / 
mice developed an acute synovitis of the tendons and small
joints of distal limbs (unpublished data), presumably result-
ing from the activity of dysregulated T cells (42).
The gp130 STAT Mutation Impairs Biological Responses to
IL-6 and IL-11. Since IL-6 and IL-11 are the only cyto-
kines that signal exclusively through gp130, we predicted
that these cytokines would fail to elicit STAT-mediated re-
sponses in gp130 STAT/ STAT mice. This was clearly demon-
strated by failure to induce type I acute phase proteins in
the liver which is a STAT-mediated response in cultured
hepatocytes (20). Furthermore, gp130 STAT/ STAT mice,
like mice either deficient for IL-6 (4, 5, 30), or containing
a conditional gp130-null allele (31), or mice transgenic for
a truncated and dominant interfering gp130 703 protein
(43), displayed impairment of T cell–dependent high affin-
ity immune and mucosal IgA responses. By contrast, con-
stitutive activation of the STAT and the SHP-2/ras/Erk
signaling cascades, as observed in IL-6 transgenic mice, re-
sulted in IgG1 plasmacytosis (44), a phenotype that was
never observed as a result of sustained activation of the
SHP-2/ras/Erk pathway in gp130 STAT/ STAT mice. Col-
lectively, these observations implicate STAT signaling,
rather than activation of the SHP-2/ras/Erk pathway, as
the driving force for IL-6–mediated plasma cell maturation.
Intriguingly, spontaneously occurring ulcerative lesions
have not been previously observed as a consequence of the201 Ernst et al.
genetic manipulation of the IL-6/LIF cytokine axis. Nota-
bly, no intestinal phenotype was observed in IL-6 /  or IL-
11R 1 /  mice, although a role for STAT3 has been pro-
posed during cell migration in epidermal wound healing
(45). Thus, it is conceivable that intestinal ulceration in
gp130 STAT/ STAT mice may result from a combination of
STAT-dependent reduction in IL-6–mediated first line de-
fense against pathogens at mucosal surfaces and impairment
of epithelial homeostasis, which is maintained in the intes-
tine, at least in part, through IL-11–mediated signaling (46).
The gp130 STAT Mutation Reduces STAT Signaling from
gp130/LIF-R  Complexes. The failure of blastocyst im-
plantation in gp130 STAT/ STAT mice resembled in all as-
pects the defect observed in LIF /  mice (6, 7) and suggests
a pivotal role for the COOH-terminal region of gp130 and
associated STAT signaling during blastocyst implantation
and possibly decidua formation. Since STAT signaling
from the mutant gp130 STAT/LIF-R  receptor hetero-
dimer was compromised in all tissues examined, the im-
plantation defect is the likely consequence of a failure to
reach a threshold level of LIF-induced STAT signaling in
the uterus of gp130 STAT/ STAT mice. However, we cannot
exclude the possibility that the gp130 STAT mutation may
also affect the implantation capacity of the uterine epithe-
lium in response to simultaneous stimulation by IL-6 and
IL-11. Although blastocyst implantation in mice individu-
ally deficient for either IL-6 or IL-11 signaling was not af-
fected (8, 9), increased IL-6 expression is observed in the
epithelial cells of the endometrium during the “implanta-
tion window” (47). The generation of IL-6 /  IL-11R  / 
mice will establish whether the simultaneous action of
these two cytokines may play a hitherto unknown indis-
pensable role during the process of uterine implantation.
This study genetically implicates gp130-mediated STAT
signaling in a number of physiological host responses af-
fecting uterine implantation, type I acute phase response,
humoral and mucosal immune response, and epithelial ho-
meostasis in the gastrointestinal tract. Surprisingly, blunting
of STAT signaling in the joint compartment resulted in the
mitogenic hyperresponsiveness of the synovial cells thereby
triggering a series of pathological responses which ulti-
mately culminated in the degeneration of the joints. This
observation is consistent with a requirement for the bal-
anced activation of the SHP-2/ras/Erk and STAT path-
ways to maintain synovial homeostasis in response to
gp130 signaling and highlights the crucial role for the LIF/
IL-6 cytokine family in retaining the integrity of joint ar-
chitecture and function. To date, no disorder has been as-
sociated with impaired gp130 signaling in humans, how-
ever, germline mutations yielding a premature stop codon
have been found in the related receptor for granulocyte
colony stimulating factor in a subset of patients with se-
vere congenital neutropenia (48). On the assumption that
gp130 truncation mutations in humans would phenocopy
at least some of the abnormalities observed in gp130 STAT
mice, one might speculate that a subset of patients with de-
generative joint diseases, female infertility, or impaired
mucosal immunity may result from nonsense mutations in
gp130 or other genetic lesions that impair gp130-mediated
STAT signaling.
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